Pharmaceutical manufacturer
Discussions related to FDA 'skinny labelling' issue. Monitored HR 7377, Modernizing Therapeutic Equivalence Rating Determination Act. Monitored S. 1463, Modernizing Therapeutic Equivalence Rating Determination Act. H.R. 2853 BLOCKING Act of 2021 (All sections of full text). S. 2910, Expanding Access to Low-Cost Generics Act of 2021 (All sections of full text). Discussions regarding S. 3799, PREVENT Pandemics Act of 2022. Discussions regarding the reauthorization of Generic Drug User Fee Amendments included in P.L.117-95, Extension of Continuing Appropriations Act. Discussions regarding improved education about digital health care. Monitored the implementation of P.L. 117-169, Inflation Reduction Act of 2022. Monitored the implementation of P.L.117-7, To prevent across-the-board direct spending cuts, and for other purposes. Monitored Medicare and prescription drug changes. Monitored discussions related to mental health legislation.
CPT - Copyright/Patent/Trademark HCR - Health Issues
24 - Commerce, Dept of (DOC) 1 - SENATE 136 - Centers For Medicare and Medicaid Services (CMS) 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 12 - White House Office
THE SMITH-FREE GROUP, LLC
1401 K Street NW Suite 1200, Washington, DC, 20005, US
MICHAEL A. GAFFIN ROBERT HICKMOTT TREVOR W. KOLEGO ROBERT HICKMOTT MICHAEL A. GAFFIN JACK S DEUSER